Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Literature DB >> 31871779

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Yuan Cheng¹, Cai He¹, Manni Wang¹, Xuelei Ma¹, Fei Mo¹, Shengyong Yang¹, Junhong Han¹, Xiawei Wei¹.

Abstract

Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Cancer epidemiology; Drug development

Year: 2019 PMID： 31871779 PMCID： PMC6915746 DOI： 10.1038/s41392-019-0095-0

Source DB: PubMed Journal: Signal Transduct Target Ther ISSN： 2059-3635

665 in total

1. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.

Authors: Shaojia Wang; Jiajia Li; Jie Xie; Fei Liu; Yachen Duan; Yong Wu; Shenglin Huang; Xianghuo He; Ziliang Wang; Xiaohua Wu
Journal: Oncogene Date: 2018-04-30 Impact factor: 9.867

2. Autocrine TGF-β1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation.

Authors: Xi Tang; Gang Tu; Guanglun Yang; Xing Wang; Linmin Kang; Liping Yang; Huan Zeng; Xueying Wan; Yina Qiao; Xiaojiang Cui; Manran Liu; Yixuan Hou
Journal: Cancer Lett Date: 2019-03-06 Impact factor: 8.679

3. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

Authors: F Crea; L Fornaro; E Paolicchi; G Masi; P Frumento; F Loupakis; L Salvatore; C Cremolini; M Schirripa; F Graziano; M Ronzoni; V Ricci; W L Farrar; A Falcone; R Danesi
Journal: Ann Oncol Date: 2011-09-16 Impact factor: 32.976

4. A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.

Authors: Calvin Rodrigues; Chitra Pattabiraman; Anjali Vijaykumar; Reety Arora; Suma Mysore Narayana; Rekha V Kumar; Dimple Notani; Patrick Varga-Weisz; Sudhir Krishna
Journal: Exp Cell Res Date: 2019-02-14 Impact factor: 3.905

5. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters.

Authors: Kyounghyun Kim; Gayathri Chadalapaka; Satya S Pathi; Un-Ho Jin; Ju-Seog Lee; Yun-Yong Park; Sung-Gook Cho; Sudhakar Chintharlapalli; Stephen Safe
Journal: Mol Cancer Ther Date: 2012-06-29 Impact factor: 6.261

6. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.

Authors: Zhiwei Zhang; Yang Yang; Xiuqiang Zhang
Journal: Life Sci Date: 2017-09-04 Impact factor: 5.037

7. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.

Authors: C A French; C L Ramirez; J Kolmakova; T T Hickman; M J Cameron; M E Thyne; J L Kutok; J A Toretsky; A K Tadavarthy; U R Kees; J A Fletcher; J C Aster
Journal: Oncogene Date: 2007-10-15 Impact factor: 9.867

8. The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

Authors: Le Hong; Gen Sun; Long Peng; Yi Tu; Zhen Wan; Haiwei Xiong; Yong Li; Weidong Xiao
Journal: Oncol Rep Date: 2018-09-12 Impact factor: 3.906

9. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.

Authors: Y Kang; H Nian; P Rajendran; E Kim; W M Dashwood; J T Pinto; L A Boardman; S N Thibodeau; P J Limburg; C V Löhr; W H Bisson; D E Williams; E Ho; R H Dashwood
Journal: Cell Death Dis Date: 2014-10-16 Impact factor: 8.469

10. Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation.

Authors: Rafael Peres; Hideki Furuya; Ian Pagano; Yoshiko Shimizu; Kanani Hokutan; Charles J Rosser
Journal: Oncotarget Date: 2016-07-12

177 in total

Review 1. Epigenetic memory in development and disease: Unraveling the mechanism.

Authors: Sam Thiagalingam
Journal: Biochim Biophys Acta Rev Cancer Date: 2020-01-23 Impact factor: 10.680

2. Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer.

Authors: Piotr Przanowski; Song Lou; Rachisan Djiake Tihagam; Tanmoy Mondal; Caroline Conlan; Gururaj Shivange; Ilyas Saltani; Chandrajeet Singh; Kun Xing; Benjamin B Morris; Marty W Mayo; Luis Teixeira; Jacqueline Lehmann-Che; Jogender Tushir-Singh; Sanchita Bhatnagar
Journal: Cancer Res Date: 2020-08-27 Impact factor: 12.701

3. Inhibition of PfMYST Histone Acetyltransferase Activity Blocks Plasmodium falciparum Growth and Survival.

Authors: Utsav Sen; Akshaykumar Nayak; Juhi Khurana; Deepu Sharma; Ashish Gupta
Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191

Review 4. The language of chromatin modification in human cancers.

Authors: Shuai Zhao; C David Allis; Gang Greg Wang
Journal: Nat Rev Cancer Date: 2021-05-17 Impact factor: 60.716

5. Regulation of SIRT2 by Wnt/β-catenin signaling pathway in colorectal cancer cells.

Authors: Chang Li; Yuning Zhou; Ji Tae Kim; Tomoko Sengoku; Michael C Alstott; Heidi L Weiss; Qingding Wang; B Mark Evers
Journal: Biochim Biophys Acta Mol Cell Res Date: 2021-01-13 Impact factor: 4.739

6. Differential regulation of LRRC37A2 in gastric cancer by DNA methylation.

Authors: Fernanda Wisnieski; Jaqueline Cruz Geraldis; Leonardo Caires Santos; Mariana Ferreira Leal; Danielle Queiroz Calcagno; Carolina Oliveira Gigek; Elizabeth Suchi Chen; Ana Carolina Anauate; Ricardo Artigiani; Samia Demachki; Paulo Pimentel Assumpção; Laercio Gomes Lourenço; Carlos Haruo Arasaki; Julie Krainer; Stephan Pabinger; Rommel Rodriguez Burbano; Marilia Arruda Cardoso Smith
Journal: Epigenetics Date: 2021-02-08 Impact factor: 4.528

7. Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection.

Authors: Ahmad M Zidan; Eman A Saad; Nasser E Ibrahim; Medhat H Hashem; Amal Mahmoud; Alaa A Hemeida
Journal: Heliyon Date: 2021-05-03